Supernus Pharmaceuticals | SUPN - 流动负债



金融业
股票价格
USD
资产
USD 1.43B
现金及等价物
USD 179.95M
销售成本
USD 59M
流动资产
USD 723.5M
流动负债
USD 347.38M
债务
USD 40.17M
EBIT
USD -21.04M
EBITDA
USD 31.6M
员工
674
EPS每股收益
USD -1.01
股本和储备
USD 1.03B
销售毛利
USD 160.06M
债务利息支出
USD 910K
利息收入
USD 2.63M
贷款资金
USD 400.38M
市值
USD 2.3B
净收入
USD -58.37M
营业费用
USD 1.03B
营业利润
USD -21.04M
普通股股本
USD 58.16M
PE价格收益
65.37
税前利润
USD -57.65M
销售收入
USD 219.1M
销售和管理费用
USD 133.64M
股票
USD 107.03M
贸易债权人
USD 5.59M
应收帐款人
USD 211.66M


流动负债 更改 日
Abbott USD 18.38B 1.88B 2026-03
ANI Pharmaceuticals USD 283.65M 44.14M 2026-06
Aurora Cannabis CAD 66.93M 79M 2026-03
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Canopy Growth CAD 158.44M 60.15M 2026-03
Cara Therapeutics USD 11.26M 216K 2026-03
Corcept Therapeutics USD 153.8M 4.62M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Novo Nordisk DKK 239.08B 13.92B 2026-06
Pacira USD 122.01M 13.22M 2026-06
Perrigo USD 1.05B 57.2M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Supernus Pharmaceuticals USD 347.38M 26.55M 2026-06
United Therapeutics USD 607.8M 8.7M 2026-06
Xeris Pharmaceuticals USD 189.57M 70.97M 2026-06